Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

Pierre Rocca; Jérôme Dumortier; Philippe Tanière; Serge Duperret; Thierry Vial; Vincent Cottin; Bertrand Delafosse; Jean Yves Scoazec; Olivier Boillot

Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

Pierre Rocca, Jérôme Dumortier, Philippe Tanière, Serge Duperret, Thierry Vial, Vincent Cottin, Bertrand Delafosse, Jean Yves Scoazec, Olivier Boillot

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

11 Citations (Scopus)

Résumé

Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

Titre traduit de la contribution	Induced interstitial pneumonitis: Role of pegylated interferon alpha 2b
langue originale	Français
Pages (de - à)	405-408
Nombre de pages	4
journal	Gastroenterologie Clinique et Biologique
Volume	26
Numéro de publication	4
état	Publié - 5 juin 2002
Modification externe	Oui

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{365cd654fd05436f8ee32d0baaf4db73,

title = "Forme pegyl{\'e}e de l'interf{\'e}ron alpha 2b et pneumopathies interstitielles diffuses",

abstract = "Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.",

author = "Pierre Rocca and J{\'e}r{\^o}me Dumortier and Philippe Tani{\`e}re and Serge Duperret and Thierry Vial and Vincent Cottin and Bertrand Delafosse and Scoazec, {Jean Yves} and Olivier Boillot",

year = "2002",

month = jun,

day = "5",

language = "Fran{\c c}ais",

volume = "26",

pages = "405--408",

journal = "Gastroenterologie Clinique et Biologique",

issn = "0399-8320",

number = "4",

}

TY - JOUR

T1 - Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

AU - Rocca, Pierre

AU - Dumortier, Jérôme

AU - Tanière, Philippe

AU - Duperret, Serge

AU - Vial, Thierry

AU - Cottin, Vincent

AU - Delafosse, Bertrand

AU - Scoazec, Jean Yves

AU - Boillot, Olivier

PY - 2002/6/5

Y1 - 2002/6/5

N2 - Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

AB - Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036105513&partnerID=8YFLogxK

M3 - Article

C2 - 12070414

AN - SCOPUS:0036105513

SN - 0399-8320

VL - 26

SP - 405

EP - 408

JO - Gastroenterologie Clinique et Biologique

JF - Gastroenterologie Clinique et Biologique

IS - 4

ER -